Before you sell to, join or invest in Outlook Therapeutics, Inc.
MentionFox check on Outlook Therapeutics, Inc.: no red flags found in 4 sources; 3 items to note (checked 6 November 2026). mentionfox.com/c/funding/outlook-therapeutics-inc-form-d-25000001
Check Outlook Therapeutics, Inc. before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.
Outlook Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2025-01-27.
Outlook Therapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on January 27, 2025. Its industry group is Biotechnology. It names Randy Thurman (Director), Yezan Haddadin (Director), Kurt Hilzinger (Director) (SEC Form D, January 27, 2025).
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
Sell to companies like Outlook Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-01-27 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Outlook Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind Outlook Therapeutics, Inc., from the filings we hold.
Biotechnology raises by companies based in New Jersey, filed within 90 days of this one, largest first.
Get an email when Outlook Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Outlook Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Outlook Therapeutics, Inc. →Get the full cited report on Outlook Therapeutics, Inc.
What the filing shows about Outlook Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Outlook Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Outlook Therapeutics, Inc.'s address as 111 S. Wood Avenue, Unit #100, Iselin, NJ 08830.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Outlook Therapeutics, Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Outlook Therapeutics, Inc. See pricing
Outlook Therapeutics, Inc. is a registered filer with the SEC (CIK 1649989) and has filed since 2023-01-06. 6 filings are on record, the latest on 2026-05-07.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Outlook Therapeutics, Inc.'s Form D of 2025-01-27 names Randy Thurman, Yezan Haddadin, Kurt Hilzinger and 7 more as its officers, directors or promoters.
Its new offerings report $97.85M sold across 4 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 763 filings in Biotechnology, totalled by week.
Randy Thurman is named as Director on the Form D that Outlook Therapeutics, Inc. filed with the SEC on 27 January 2025, one of 10 people that filing names.
Yezan Haddadin is named as Director on the Form D that Outlook Therapeutics, Inc. filed with the SEC on 27 January 2025, one of 10 people that filing names.
Kurt Hilzinger is named as Director on the Form D that Outlook Therapeutics, Inc. filed with the SEC on 27 January 2025, one of 10 people that filing names.
Lawrence Kenyon is named as Executive Officer and Director on the Form D that Outlook Therapeutics, Inc. filed with the SEC on 27 January 2025, one of 10 people that filing names.
Faisal Sukhtian is named as Director on the Form D that Outlook Therapeutics, Inc. filed with the SEC on 27 January 2025, one of 10 people that filing names.
Andong Huang is named as Director on the Form D that Outlook Therapeutics, Inc. filed with the SEC on 27 January 2025, one of 10 people that filing names.
Gerd Auffarth is named as Director on the Form D that Outlook Therapeutics, Inc. filed with the SEC on 27 January 2025, one of 10 people that filing names.
Julian Gangolli is named as Director on the Form D that Outlook Therapeutics, Inc. filed with the SEC on 27 January 2025, one of 10 people that filing names.
Julia Haller is named as Director on the Form D that Outlook Therapeutics, Inc. filed with the SEC on 27 January 2025, one of 10 people that filing names.
Jeff Evanson is named as Executive Officer on the Form D that Outlook Therapeutics, Inc. filed with the SEC on 27 January 2025, one of 10 people that filing names.
10 people named on the filing — 2 holding an executive role and 8 as directors only.
Named as of the 2025-01-27 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Outlook Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Outlook Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Outlook Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Outlook Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Outlook Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Outlook Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
https://mentionfox.com/funding/outlook-therapeutics-inc-form-d-25000001